BR112022017770A2 - Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso - Google Patents

Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso

Info

Publication number
BR112022017770A2
BR112022017770A2 BR112022017770A BR112022017770A BR112022017770A2 BR 112022017770 A2 BR112022017770 A2 BR 112022017770A2 BR 112022017770 A BR112022017770 A BR 112022017770A BR 112022017770 A BR112022017770 A BR 112022017770A BR 112022017770 A2 BR112022017770 A2 BR 112022017770A2
Authority
BR
Brazil
Prior art keywords
individual
treatment
kit
panel
isolated polynucleotide
Prior art date
Application number
BR112022017770A
Other languages
English (en)
Portuguese (pt)
Inventor
W Whitaker John
Dhali Zafrin
Sun Hong
Lu Haiping
Li Xiaojun
Wu Wilson
Luo Wen
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of BR112022017770A2 publication Critical patent/BR112022017770A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112022017770A 2020-03-06 2021-02-23 Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso BR112022017770A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (1)

Publication Number Publication Date
BR112022017770A2 true BR112022017770A2 (pt) 2022-11-29

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017770A BR112022017770A2 (pt) 2020-03-06 2021-02-23 Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso

Country Status (13)

Country Link
US (1) US20230193388A1 (ko)
EP (1) EP4106872A4 (ko)
JP (1) JP2023515665A (ko)
KR (1) KR20230005816A (ko)
CN (1) CN115515680A (ko)
AR (1) AR121515A1 (ko)
AU (1) AU2021231683A1 (ko)
BR (1) BR112022017770A2 (ko)
CA (1) CA3174572A1 (ko)
IL (1) IL296168A (ko)
MX (1) MX2022010816A (ko)
TW (1) TW202146660A (ko)
WO (1) WO2021178166A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901885B2 (en) * 2006-05-09 2011-03-08 Dsm Ip Assets B.V. Genes and markers in type 2 diabetes and obesity
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
US20110189663A1 (en) * 2007-03-05 2011-08-04 Cancer Care Ontario Assessment of risk for colorectal cancer
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20140274764A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
ES2726650T3 (es) * 2014-03-14 2019-10-08 Caredx Inc Métodos de monitorización de terapias inmunosupresoras en un receptor de trasplante

Also Published As

Publication number Publication date
CN115515680A (zh) 2022-12-23
WO2021178166A1 (en) 2021-09-10
TW202146660A (zh) 2021-12-16
IL296168A (en) 2022-11-01
EP4106872A1 (en) 2022-12-28
US20230193388A1 (en) 2023-06-22
AU2021231683A1 (en) 2022-09-22
JP2023515665A (ja) 2023-04-13
AR121515A1 (es) 2022-06-08
EP4106872A4 (en) 2024-04-10
CA3174572A1 (en) 2021-09-10
KR20230005816A (ko) 2023-01-10
MX2022010816A (es) 2022-12-13

Similar Documents

Publication Publication Date Title
Gkatza et al. Cytosine-5 RNA methylation links protein synthesis to cell metabolism
Sankowski et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques
Kuan et al. An epigenome-wide DNA methylation study of PTSD and depression in World Trade Center responders
Dias et al. β-catenin mediates stress resilience through Dicer1/microRNA regulation
Wang et al. Genome-wide differential expression of synaptic long noncoding RNAs in autism spectrum disorder
James et al. Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum
Calligaris et al. Blood transcriptomics of drug-naive sporadic Parkinson’s disease patients
Gavin et al. Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis
Fisher et al. Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms
Munkholm et al. A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder
Peeters et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
Berge et al. The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells
Berta et al. Gene expression profiling of cutaneous injured and non-injured nociceptors in SNI animal model of neuropathic pain
Katoh et al. Reciprocal changes of H3K27ac and H3K27me3 at the promoter regions of the critical genes for endometrial decidualization
Lagerstedt et al. H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury
Colicino et al. Telomere length, long-term black carbon exposure, and cognitive function in a cohort of older men: the VA Normative Aging Study
Nevalainen et al. Transcriptomic and epigenetic analyses reveal a gender difference in aging-associated inflammation: the Vitality 90+ study
Pasinetti et al. Select non-coding RNA in blood components provide novel clinically accessible biological surrogates for improved identification of traumatic brain injury in OEF/OIF Veterans
Gill et al. Moderate blast exposure alters gene expression and levels of amyloid precursor protein
Fries et al. Integrated transcriptome and methylome analysis in youth at high risk for bipolar disorder: a preliminary analysis
Li et al. Methyl CpG Binding Domain Ultra‐Sequencing: a novel method for identifying inter‐individual and cell‐type‐specific variation in DNA methylation
Kebir et al. Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis
BR112022017770A2 (pt) Polinucleotídeo isolado; painel de polinucleotídeos isolados; kit que compreende o polinucleotídeo isolado ou painel; microarranjo; reagente; kit que compreende o reagente; kit que compreende o polinucleotídeo isolado ou painel; método de diagnóstico complementar; método para classificar um indivíduo para elegibilidade para um tratamento; método para rastrear um indivíduo ou uma população de indivíduos para um tratamento; método para monitorar um indivíduo durante um tratamento; método para identificar um alvo de fármaco; método para o tratamento de doença ou transtorno do sistema nervoso central (snc) em um indivíduo; uso
Jones et al. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes
Wei et al. Co-morbidity of personality disorder in schizophrenia among psychiatric outpatients in China: data from epidemiologic survey in a clinical population